PDA Options: To view abstract content with the ability to bookmark to set up an itinerary that you can download and save to your PDA or computer, click on MY ITINERARY in the banner above; then proceed by searching the online database.



Sponsored by
Category Index Expand / Collapse All
Click on one of the following letters below to display a list of alphabetized categories.
Click the checkbox next to each item to bookmark.
A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
 A


Expand/Collapse Item Adjuvant Chemotherapy
Expand/Collapse Item Adjuvant Endocrine Therapy
  [12] Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies.
  [13] BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.
  [14] Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8.
  [15] Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.
  [44] The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST.
  [66] Effect of tibolone on breast cancer recurrence: LIBERATE trial bone sub-study.
  [1128] Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study.
  [1129] A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms.
  [1130] Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
  [1131] The effect of quantitative oestrogen receptor expression on recurrence in postmenopausal women with early stage breast cancer.
  [1132] A randomised study comparing the effects of anastrozole (A), letrozole (L), exemestane (E) and tamoxifen (T) on coagulation.
  [1133] Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the TEAM trial neuropsychological side study.
  [1134] NCIC CTG MA.17: hormone receptor expression of in-breast recurrences and contralateral primary breast cancers arising on aromatase inhibitors.
  [1135] Administrative claims: a novel approach in monitoring long term adherence to anti-hormonal therapy in breast cancer.
  [1136] Health-related quality-of-life and psychological distress of postmenopausal breast cancer patients after surgery during the randomized trial, N-SAS BC 03, comparing further tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1 to 4 years: the final results.
  [1137] Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE).
  [1138] Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
  [1140] Tolerance and consecutive patients adherence to hormonal treatment for early breast cancer.
  [1141] The decrease in grip strength in aromatase inhibitor-induced arthralgia is associated with extremes in body mass index and increased tenosynovial abnormalities.
  [1142] Effects of switching aromatase inhibitors on arthralgia: the ATOLL study.
  [1143] Bone effects of exemestane vs. tamoxifen within the TEAM trial: results of a prospective randomized bone sub study.
  [1144] A global perspective on the use of aromatase inhibitors in early-stage breast cancer.
  [1145] A randomised study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnover.
  [1146] Effects of obesity on anastrozole response in a mouse model of postmenopausal breast cancer.
  [1147] Vitreo-retinal traction and anastrozole use.
  [1148] Menopause surveillance recommendations for patients with endocrine responsive breast cancer.
  [1149] A synthetic PPARγ ligand sensitizes breast cancer cells to tamoxifen-induced apoptosis.
  [1150] Endocrine effects of adjuvant letrozole versus tamoxifen in hormone responsive postmenopausal early breast cancer patients: results from the HOBOE randomized trial.
  [1151] Adriamycin and cyclophosphamide followed by tamoxifen, versus the combination of gonadotropin-releasing hormone analog and tamoxifen, in the treatment of premenopausal endocrine-responsive node-negative breast cancer.
  [1152] A randomised study comparing the effects of anastrozole and letrozole on lipid metabolism.
  [1153] Zolandronic acid protective effect on bone loss in postmenopausal women switched from tamoxifen to letrozole in the treatment of early breast cancer.
  [1154] Effect of exemestane on bone turnover markers and bone mineral density (BMD): 2 year results of the Dutch/Belgian Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
  [4159] Results of the randomized phase II trial of adjuvant anastrozole versus anastrozole plus fulvestrant in hormone-receptor-positive postmenopausal breast cancer patients with bone marrow micrometastasis (ABCSG trial 21).
 
 

Abstract Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved